Protective effect of A/H1N1 vaccination in immune-mediated disease--a prospectively controlled vaccination study
Open Access
- 14 December 2011
- journal article
- research article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 51 (4), 695-700
- https://doi.org/10.1093/rheumatology/ker389
Abstract
Objectives. To assess the 2009 influenza vaccine A/H1N1 on antibody response, side effects and disease activity in patients with immune-mediated diseases. Methods. Patients with RA, SpA, vasculitis (VAS) or CTD (n = 149) and healthy individuals (n = 40) received a single dose of adjuvanted A/H1N1 influenza vaccine. Sera were obtained before vaccination, and 3 weeks, 6 weeks and 6 months thereafter. A/H1N1 antibody titres were measured by haemagglutination inhibition (HAI) assay. Seroprotection was defined as specific antibody titre ≥ 1 : 40, seroconversion as 4-fold increase in antibody titre. Results. Titres increased significantly in patients and controls with a maximum at Week 3, declining to levels below protection at Month 6 (P < 0.001). Seroprotection was more frequently reached in SpA and CTD than in RA and VAS (80 and 82% and 57 and 47%, respectively). There was a significantly negative impact by MTX (P < 0.001), rituximab (P = 0.0031) and abatacept (P = 0.045). Other DMARDs, glucocorticoids and TNF blockers did not significantly suppress response (P = 0.06, 0.11 and 0.81, respectively). A linear decline in response was noted in patients with increasing age (P < 0.001). Disease reactivation possibly related to vaccination was suspected in 8/149 patients. No prolonged side effects or A/H1N1 infections were noted. Conclusions. The results show that vaccination response is a function of disease type, intensity and character of medication and age. A single injection of adjuvanted influenza vaccine is sufficient to protect a high percentage of patients. Therefore, differential vaccination recommendations might in the future reduce costs and increase vaccination acceptance.Keywords
This publication has 15 references indexed in Scilit:
- EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseasesAnnals Of The Rheumatic Diseases, 2010
- Vaccination and autoimmune rheumatic diseasesAutoimmunity Reviews, 2008
- Low influenza-vaccination rate among adults receiving immunosuppressive therapy for systemic inflammatory diseaseAnnals Of The Rheumatic Diseases, 2008
- Rapid Decline of Influenza Vaccine–Induced Antibody in the Elderly: Is It Real, or Is It Relevant?The Journal of Infectious Diseases, 2008
- Influenza vaccination of patients with systemic lupus erythematosus: Safety and immunogenecity issuesAutoimmunity Reviews, 2007
- Influenza vaccination as model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patientsRheumatology, 2006
- Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNF blockersAnnals Of The Rheumatic Diseases, 2006
- Safety and Efficacy of Vaccination Against Influenza in Patients With Rheumatoid ArthritisJournal of Immunology Research, 2006
- Predictors of infection in rheumatoid arthritisArthritis & Rheumatism, 2002
- Infectious diseases in systemic lupus erythematosus: risk factors, management and prophylaxisBest Practice & Research Clinical Rheumatology, 2002